PEDIATRICS Vol. 119 Supplement March 2007, pp. S150-S162 (doi:10.1542/peds.2006-2023H)
SUPPLEMENT ARTICLE |
Bisphosphonates: Mode of Action and Pharmacology
Botnar Research Centre and Oxford University Institute of Musculoskeletal Sciences, Oxford, United Kingdom
The profound effects of the bisphosphonates on calcium metabolism were discovered over 30 years ago, and they are now well established as the major drugs used for the treatment of bone diseases associated with excessive resorption. Their principal uses are for Paget disease of bone, myeloma, bone metastases, and osteoporosis in adults, but there has been increasing and successful application in pediatric bone diseases, notably osteogenesis imperfecta. Bisphosphonates are structural analogues of inorganic pyrophosphate but are resistant to enzymatic and chemical breakdown. Bisphosphonates inhibit bone resorption by selective adsorption to mineral surfaces and subsequent internalization by bone-resorbing osteoclasts where they interfere with various biochemical processes. The simpler, non–nitrogen-containing bisphosphonates (eg, clodronate and etidronate) can be metabolically incorporated into nonhydrolysable analogues of adenosine triphosphate (ATP) that may inhibit ATP-dependent intracellular enzymes. In contrast, the more potent, nitrogen-containing bisphosphonates (eg, pamidronate, alendronate, risedronate, ibandronate, and zoledronate) inhibit a key enzyme, farnesyl pyrophosphate synthase, in the mevalonate pathway, thereby preventing the biosynthesis of isoprenoid compounds that are essential for the posttranslational modification of small guanosine triphosphate (GTP)-binding proteins (which are also GTPases) such as Rab, Rho, and Rac. The inhibition of protein prenylation and the disruption of the function of these key regulatory proteins explains the loss of osteoclast activity. The recently elucidated crystal structure of farnesyl diphosphate reveals how bisphosphonates bind to and inhibit at the active site via their critical nitrogen atoms. Although bisphosphonates are now established as an important class of drugs for the treatment of many bone diseases, there is new knowledge about how they work and the subtle but potentially important differences that exist between individual bisphosphonates. Understanding these may help to explain differences in potency, onset and duration of action, and clinical effectiveness.
Key Words: bone resorption • osteoclasts • bisphosphonates • osteoporosis
Abbreviations: PPi—inorganic pyrophosphate • ATP—adenosine triphosphate • FPP—farnesyl diphosphate • GGPP—geranylgeranyl diphosphate • FPPS—farnesyl pyrophosphate synthase
Accepted Oct 5, 2006.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Chen, X.-M. Liu, K. C. Rice, X. Li, F. Yu, R. A. Reinhardt, K. W. Bayles, and D. Wang Tooth-Binding Micelles for Dental Caries Prevention Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4898 - 4902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Almazrooa and S.-B. Woo Bisphosphonate and Nonbisphosphonate-Associated Osteonecrosis of the Jaw: A Review J Am Dent Assoc, July 1, 2009; 140(7): 864 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Weinstein, P. K. Roberson, and S. C. Manolagas Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy N. Engl. J. Med., January 1, 2009; 360(1): 53 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Perman, A. W. Lucky, J. E. Heubi, and R. G. Azizkhan Severe Symptomatic Hypocalcemia in a Patient With RDEB Treated With Intravenous Zoledronic Acid Arch Dermatol, January 1, 2009; 145(1): 95 - 96. [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Bianchi Diagnosis and Treatment of Bone Fragility in Childhood IBMS BoneKEy, September 1, 2008; 5(9): 323 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yan, S. Chen, Y. Zhang, X. Li, Y. Li, X. Wu, J. Yuan, A. G. Robling, R. Karpur, R. J. Chan, et al. Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1 Hum. Mol. Genet., April 1, 2008; 17(7): 936 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Mellor, S. Haugland, K. C. Smith, R. M. Powell, J. Archer, T. J. Scase, E. J. Villiers, P. E. McNeil, C. Nixon, C. Knott, et al. Histopathologic, Immunohistochemical, and Cytologic Analysis of Feline Myeloma-Related Disorders: Further Evidence for Primary Extramedullary Development in the Cat Vet. Pathol., March 1, 2008; 45(2): 159 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.B. Kimmel Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates Journal of Dental Research, November 1, 2007; 86(11): 1022 - 1033. [Abstract] [Full Text] [PDF]
|
|
